News

Corona/COVID 19 - INNO4COV-19 - "Innovation hub" project (1st deadline on 30 November 2020)

Published on
| 5 years ago
Programmes
  • ICT
  • NMBP
  • Health

INNO4COV-19 OPEN CALL - Boosting Innovation for COVID-19 Diagnostic, Prevention and Surveillance

Are you working for a company active in healthcare,  medicine, biotech, biopharma, and/or IT-related topics (e.g. robotics, automation, electronics, nanotech, etc)? Then have a look at this accessible funding scheme (up to 100k€ subsidy). 

Submission deadlines in November 2020, March 2021 and May 2021.

INNO4COV-19 at a Glance

Create a “lab-to-fab” platform and collaboration resource to enable companies and reference laboratories to develop and implement innovative technologies to fight COVID-19.

Website: www.inno4cov19.eu

The INNO4COV-19 Project aims to support the full development to market uptake of technologies at TRL6-7 or higher. It Provides funding to third parties to archive the desiderated objectives.

Eligibility criteria

  • Companies or small consortia of companies established in one of the EU Member States or H2020 associated countries.
  • The sectors of focus may include healthcare / medicine / biotech / biopharma, and IT-related topics (e.g. robotics, automation, electronics, nanotech, etc).

What they offer

  • Financial support - Up to EUR 100,000 (100% of the total cost of the project)
  • Tailored support - Guidance from a network of experts at a technical, business and regulatory level for bringing your innovation to the market
  • Access to specific facilities and infrastructure - Providing added value to your innovations
  • Media exposure - Highlights through our network

Key dates

The applications will be considered in three different rounds.

  • NOVEMBER 2020 ROUND - Deadline: 30/11/2020 – Funding decision: +40days
  • MARCH 2021 ROUND - Deadline: 31/03/2021 – Funding decision: +40days
  • May 2021 ROUND - Deadline: 31/05/2021 – Funding decision: +40days

More information on the website of the call: www.inno4cov19.eu/open-call

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2068 articles available Browse all news
  • Research Infrastructures
  • Health
  • Digital, Industry & Space
  • Climate, Energy, Mobility

Lasers4EU 6th Transnational Access programme for laser research and innovation

The Lasers4EU project consortium of research infrastructures provides access to state-of-the-art laser technologies and services from primary and secondary laser sources to a wide range of laser-based instruments and techniques at 27 leading laser research institutions across Europe. More information is available in their mission and on the...

Read more
  • Research Infrastructures
  • Digital, Industry & Space
  • Climate, Energy, Mobility

Ready-PV first call for Transnational and Virtual Access to Advanced PV Research Infrastructure

The READY-PV project consortium of research infrastructures (Reliability Evaluation Through Analytics and Data for Emerging Technology in Photovoltaics) opened its first call for Transnational Access (TA = on-site) and Virtual Access (VA = remote), providing the European photovoltaic research community with free-of-charge access to an integrated...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.